---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-21-027569"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T18:22:33.753484+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Director Michael Bonney resigns from Bristol-Myers board to become Executive Chairman of Alnylam

## Summary
- Bonney resigned effective August 3, 2021, in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals.
- Board set number of directors at ten, down from the prior size (not specified).
- No other changes to board composition or officer positions disclosed.

## SEC filing metadata
- accession: 0001140361-21-027569
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000114036121027569/0001140361-21-027569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000114036121027569/brhc10027837_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-21-027569
- JSON: https://secwatch.observer/filing/0001140361-21-027569.json
- Plain text: https://secwatch.observer/filing/0001140361-21-027569.txt

## Key facts
- Executive change
  Michael Bonney resigned as Director at BRISTOL MYERS SQUIBB CO.
  - Action: resigned
  - Role: Director
  source text: On August 3, 2021, Mr. Michael Bonney resigned from the Board of Directors of Bristol-Myers Squibb Company in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals Inc .
  evidence_url: https://www.sec.gov/Archives/edgar/data/14272/000114036121027569/0001140361-21-027569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.